Abstract 205P
Background
CTCF-binding site (BS) occupancy is plastic, tissue specific and altered in cancer. This principle underlies some fragmentomics methods. We hypothesized that ChIP-Seq of plasma CTCF-cfDNA might identify CTCF-BSs selectively occupied in cancer and that, having removed all nucleosomes or other non-CTCF bound cfDNA by CTCF immunoprecipitation (IP), the presence of cfDNA fragments corresponding to sites selectively CTCF occupied in cancer may be tested for by PCR. We now report a novel liquid biopsy method, and initial results, based on this principle.
Methods
(i) Identification of CTCF-BSs selectively occupied in cancer samples. Plasma samples were collected from healthy volunteers (n=5), and patients with inflammatory conditions (n=5) or cancer (n=5). IP was performed using anti-CTCF coated magnetic beads and immunoprecipitated cfDNA was extracted, amplified and sequenced on an Illumina platform. (ii) We developed specific qPCR assays for 10 CTCF-BS sequences that we observed to be preferentially bound in the plasma of cancer patients vs either inflammatory conditions or healthy subjects. The panel of qPCR assays was tested on CTCF associated cfDNA isolated from plasma samples (1ml) obtained from patients diagnosed with a variety of common solid cancer diseases (n=48).
Results
We observed that specific CTCF IP resulted in isolation of cfDNA fragments with a frequency peak in the 30-80bp range that was not present in negative controls (mouse-IgG). These short cfDNA fragments included previously described CTCF binding sites. Moreover, CTCF binding sites were not randomly distributed on cfDNA fragments but located at the centre of each fragment. Among the CTCF occupied binding sites observed, we identified 29 sites that were significantly differentially bound in cancer. We observed highly sensitive and specific qPCR test results for a number of common solid cancer diseases including high sensitivity at disease stage I and II.
Conclusions
This is the first demonstration of IP of plasma CTCF-cfDNA. IP followed by multiplex PCR may form the basis of a rapid, low cost liquid biopsy method that obviates expensive library preparation and NGS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Belgian Volition.
Funding
Belgian Volition.
Disclosure
D. Pamart, J-V. Turatsinze, B. Cuvelier, J-V. Turatsinze: Financial Interests, Personal, Full or part-time Employment: Belgian Volition. M. Herzog: Financial Interests, Personal, Full or part-time Employment: Belgian Volition; Financial Interests, Personal, Stocks/Shares: VolitionRx. J. Micallef: Financial Interests, Personal, Officer, Chief Scientific Officer: VolitionRx Ltd; Financial Interests, Personal, Stocks/Shares: VolitionRx Ltd.
Resources from the same session
196P - Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts
Presenter: Yanjun Xu
Session: Poster session 01
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01